Theriva Corp (TOVX) - יחס שווי שוק לרווח נקי

The price chart for Theriva Biologics, Inc. (TOVX) illustrates the price action of an asset whose operating model relies on external contractors for the development of viral vectors and clinical tests. The current metric stands at -0.60. Theriva Biologics, Inc. (TOVX) is developing microbiome protection and anti-tumor therapies. Key growth drivers will include the results of the VCN-01 study, the efficacy of combination therapy, and a potential sale of the business to a major investor.
פילוחים אנליטיים של חברת Theriva Biologics, Inc.

The analyst evaluates the issuer's credit quality through the lens of market expectations. The absence of commercial products at Theriva Biologics, Inc. (TOVX) confirms its current stage of investment-driven oncology development. A P/E valuation reflects the cost of a single unit of net profit by dividing the share price by earnings. The trend of this indicator reveals the balance between speculative demand and actual capital efficiency. Sharp fluctuations in the line signal the asset's high sensitivity to regulatory risks.